Edition:
India

GlaxoSmithKline - FDA Approved Nucala For Use In Children As Young As 6 Years Old With Severe Eosinophilic Asthma


Friday, 13 Sep 2019 

Sept 12 (Reuters) - GlaxoSmithKline PLC ::NUCALA IS THE FIRST BIOLOGIC APPROVED IN THE US FOR SIX TO 11-YEAR-OLD CHILDREN WITH SEVERE EOSINOPHILIC ASTHMA.GLAXOSMITHKLINE PLC - FDA APPROVED NUCALA (MEPOLIZUMAB) FOR USE IN CHILDREN AS YOUNG AS 6 YEARS OLD WITH SEVERE EOSINOPHILIC ASTHMA.